We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

NOXXON Initiates First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer® NOX-A12

News   Nov 03, 2009

 
NOXXON Initiates First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer® NOX-A12
 
 
Advertisement
 

RELATED ARTICLES

Mass Spectrometry Shows Potential for Rapid SARS-CoV-2 Detection

News

Signature peptides of the SARS-CoV-2 virus in clinical samples (nasopharyngeal swabs) have been detected by mass spectrometry in 3 minutes and without specific reagents. It provides a proof of concept of the use of this method as a possible alternative to PCR, currently the reference method.

READ MORE

Enzyme Has Newly-Discovered Potential To Clear Huntington's Protein

News

Scientists have identified an enzyme that could play a central role in developing a new route of treatment for Huntington's disease.

READ MORE

Implanted Mouse Stem Cells Regain Their Function in Spinal Cord Injury

News

Researchers have reported successful regaining of function after implanting highly specialized grafts of neural stem cells directly into spinal cord injuries in mice.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cell Science Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE